Discontinuation of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) at risk of progressive multifocal leukoencephalopathy (PML) is associated with disease reactivation. Forty-two RRMS patients, who switched from an extended interval dose (EID) of natalizumab to ocrelizumab, underwent magnetic resonance imaging (MRI) and clinical monitoring during washout and after ocrelizumab starting. During the first 3 months, disease reactivation was observed in five (12%) patients; 6 months after ocrelizumab starting, no further relapses were recorded, and Expanded Disability Status Scale (EDSS) remained stable in 38 (90%) patients. In conclusion, ocrelizumab could be considered a choice to mitigate the risk of disease reactivation in patients previously treated with natalizumab-EID.

中文翻译：

---

有 PML 风险的 RRMS 患者改用 ocrelizumab 之前接受过延长间隔给药那他珠单抗治疗

在有进行性多灶性白质脑病 (PML) 风险的复发缓解型多发性硬化 (RRMS) 患者中停用那他珠单抗与疾病再激活有关。42 名 RRMS 患者从那他珠单抗的延长间隔剂量 (EID) 转换为 ocrelizumab，在冲洗期间和 ocrelizumab 开始后接受了磁共振成像 (MRI) 和临床监测。在前 3 个月内，5 名 (12%) 患者观察到疾病复发；ocrelizumab 开始后 6 个月，没有记录到进一步的复发，并且有 38 名（90%）患者的扩展残疾状态量表 (EDSS) 保持稳定。总而言之，ocrelizumab 可被视为降低先前接受那他珠单抗-EID 治疗的患者疾病再激活风险的一种选择。